别名 DS - Disseminated sclerosis、Disseminated Sclerosis、Disseminated sclerosis + [50] |
简介 An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) |
靶点 |
作用机制 GR激动剂 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-10-26 |
作用机制 EDG6激动剂 [+2] |
在研机构 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-10-12 |
靶点 |
作用机制 CD49d拮抗剂 |
在研机构 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-08-24 |
开始日期9999-09-09 |
申办/合作机构- |
开始日期2639-04-20 |
申办/合作机构- |
开始日期2025-01-01 |
申办/合作机构 |